Senti Biosciences Holdings
SNTI
28 hedge funds and large institutions have $7.64M invested in Senti Biosciences Holdings in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
17% more funds holding
Funds holding: 24 → 28 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 2.85% → 2.76% (-0.09%)
46% less capital invested
Capital invested by funds: $14.3M → $7.64M (-$6.62M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Triatomic Management
Palo Alto,
California
|
+$87.5K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$48.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.8K |
| 4 |
VF
Virtu Financial
New York
|
+$33.9K |
| 5 |
Renaissance Technologies
New York
|
+$16.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$268K |
| 2 |
Morgan Stanley
New York
|
-$227K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$72.7K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$69.9K |
| 5 |
Citigroup
New York
|
-$17.1K |
SNTI Hedge Fund Activity: Q2 2023 in Review
28 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q2 2023, worth a combined $7.64M — down 46% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SNTI positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Triatomic Management, adding an estimated $87.5K. The largest seller was NEA Management Company, cutting an estimated $268K.
- 28 institutional investors held Senti Biosciences Holdings (SNTI) as of Q2 2023, up from 24 in Q1 2023.
- Funds reported $7.64M of Senti Biosciences Holdings stock for Q2 2023, down 46% quarter-over-quarter.
- 6 funds opened new Senti Biosciences Holdings positions in Q2 2023 and 2 closed out, a net change of +4 holders.
- The largest Senti Biosciences Holdings buyer in Q2 2023 was Triatomic Management, an estimated $87.5K added.
- The largest Senti Biosciences Holdings seller in Q2 2023 was NEA Management Company, an estimated $268K sold.
Based on aggregated 13F filings for Q2 2023.